Evidence map›Paper›PMID 41522744›Full record

ArticleJournal of gastrointestinal oncology2025

The effect of neoadjuvant chemoradiotherapy on perioperative outcomes in rectal cancer patients following stoma reversal-a retrospective cohort analysis.

Mary Junak, Rosemarie Turk, Mohammad Afaque Alam, Eli Thompson, David Schaub, Joseph Gunderson, Anesu S Masango, Srikar Kollipara, Andrea Moreno, Daniom Tecle and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mary JunakDepartment of Surgery, University of Wisconsin-Madison, Madison, WI, USA.
Rosemarie TurkDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Mohammad Afaque AlamDepartment of Surgery, Louisiana State University, New Orleans, LA, USA.
Eli ThompsonDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
David SchaubDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Joseph GundersonDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Anesu S MasangoDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Srikar KolliparaDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Andrea MorenoDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Daniom TecleDepartment of Surgery, University of Arizona, Tucson, AZ, USA.
Valentine N NfonsamDepartment of Surgery, Louisiana State University, New Orleans, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anastomotic leak after reversal of an ostomy is a significant complication in rectal cancer patients. The effects of neoadjuvant chemoradiotherapy (NCRT) on outcomes following stoma reversal are not well established. The aim of our study was to evaluate the effect of NCRT on outcomes in rectal cancer patients following stoma reversal. Methods: We performed a [2005-2012] retrospective cohort analysis of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP), including adult (≥18 years) rectal cancer patients who had elective stoma reversal. Patients were stratified into those who received NCRT and those who did not. Primary outcomes were anastomotic leak and major complications. Secondary outcomes were mortality and length of stay (LOS). Regression analysis was performed confounding variables. Results: We identified a total of 461 patients of which 259 received NCRT while 202 did not. The mean age was 52±10 years, and 28% had an American Society of Anesthesiologists (ASA) class III-IV. Overall, the rate of anastomotic leak was 6.8%. Major complications were seen in 5.6% of patients with the most common complication being organ space infection (3.2%). There was no difference between the two groups regarding anastomotic leak (7.9% Conclusions: Our findings suggested that NCRT for rectal cancer does not increase morbidity following stoma closure. Stoma closure is safe and should not be withheld based on NCRT.

Indexed as

chemoradiotherapyoutcomesRectal cancerstoma reversal

Identifiers

PMID41522744
PMCPMC12780678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.